

Expansion of HLA-G-Expressing Myeloid-Derived Suppressor Cells in Patients with Chronic Hepatitis B Virus Infection

Hai-Yan Lv¹, Jing-Bo Li¹, Aifen Lin², Dan-Ping Xu¹, Bao-Guo Chen¹, Hua-Zhong Chen³ and Wei-Hua Yan^{1*}

¹Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China

²Human Tissue Bank, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China

³Department of Infection Diseases, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China

*Corresponding author: Wei-Hua Yan, Medical Research Center, Taizhou Hospital of Zhejiang Province, Wenzhou Medical University, Linhai, Zhejiang, China, Tel: +86-576-85199347; Fax: +86-576-85199876; E-mail: yanwhcom@yahoo.com

Received date: May 23, 2017; Accepted date: July 18, 2017; Published date: July 24, 2017

Copyright: ©2017 Lv HY, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Both human leukocyte antigen-G (HLA-G) and myeloid-derived suppressor cells (MDSCs) was associated with the pathogenesis of infectious diseases. Whether peripheral MDSCs express HLA-G during virus infection remains unknown. We investigated the frequency of HLA-G⁺ MDSCs and its subsets in patients infected with chronic hepatitis B (CHB). In this study, frequencies of peripheral MDSCs (Lin1-HLA-DR-CD33⁺CD11b⁺) and HLA-G expressing subsets from 50 CHB patients and 27 normal controls were analyzed using flow cytometry. Data revealed the median percentage of MDSCs was not significantly different between the CHB patients and controls (0.30% vs. 0.29%; $p=0.884$). Among MDSCs, similar frequency was observed for CD14⁺ monocytic MDSC (mMDSCs; 31.25% vs. 23.35%; $p=0.063$) and CD15⁺ granulocytic MDSC (gMDSCs; 22.60% vs. 21.55%; $p=0.558$) between the two groups. However, HLA-G⁺ MDSCs was significantly increased in CHB patients compared with that of controls (3.30% vs. 0.50%; $p<0.001$). Furthermore, both HLA-G⁺ mMDSCs (0.99% vs. 0.00%; $p<0.001$) and HLA-G⁺ gMDSC (0.78% vs. 0.00%; $p<0.001$) were also dramatically increased in CHB patients. Particularly, HLA-G⁺ gMDSC was inversely correlated to the viral DNA loads and significantly increased in HBeAb positive patients. Summary, this work reports for the first time HLA-G⁺ MDSCs, a new population of peripheral MDSCs, were expanded in CHB patients; however, its clinical relevance yet to be further explored.

Keywords: HLA-G; Myeloid derived suppressor CELLS; HBV; Infection

Introduction

Hepatitis B virus (HBV) is one of the most common infectious agents for humans by affecting an estimated 240 million people worldwide [1]. HBV infection could cause liver damage such as acute and chronic hepatitis, cirrhosis and hepatocellular carcinoma, which is particularly occurred in Asian countries [2]. During HBV infection, both innate and adaptive host immune response plays a critical role in pathogenesis and clinical outcomes of hepatitis B. Multiple immune cells, such as cytotoxic T lymphocytes, regulatory T cells, natural killer cells, dendritic cells and B cells are important in the immune regulation of HBV infection and determination whether HBV infection is cleared or persists [3,4].

Myeloid-derived suppressor cells (MDSCs), a heterogeneous population of granulocytic (gMDSC) or monocytic (mMDSC) cells, have been reported in a variety of virus infection associated pathologies [5]. The hallmark of MDSCs is their ability to suppress both innate and adaptive immune responses [6]. Suppressive factors expressed by MDSCs, such as arginase-1, reactive oxygen species (ROS), inducible nitric oxide synthase (iNOS) and program death ligand 1 (PDL-1), play pivotal roles in inhibition of T cell, B cell and natural killer cell (NK) mediated immune responses, and in induction of tolerogenic Tregs and regulatory dendritic cells (DCs) [7].

In the context of virus infection, hepatitis C virus (HCV) infection could promote peripheral MDSCs accumulation and suppress T cell

responses [8,9]. Also, elevated peripheral MDSCs in chronic hepatitis C patients was observed to be related to HCV-RNA copies [10]. In Human immunodeficiency virus (HIV) infected patients, gMDSCs were expanded and could induce T-cell anergy by suppressing CD3 ζ expression [11]. Garg et al. [12] found that CD4⁺CD25⁺FoxP3⁺ regulatory T-cell could be induced by MDSCs promoted with the HIV type 1 gp120. In other pathogens, studies reported splenic MDSCs was increased with influenza A virus and vaccinia [13,14], and adenovirus can induce gMDSCs to suppress NK cell proliferation and activation via hydrogen peroxide in C57BL/6 mice [15]. These studies indicated that MDSCs could provide an additional means for virus to escape from host immune clearance.

The immunotolerant HLA-G is a member of the non-classical HLA class I antigen, and its ectopic expression was addressed in amounts of previous studies, where HLA-G was markedly increased during various virus infection and associated with disease progression [16]. HLA-G acts mainly through two inhibitory receptors including immunoglobulin-like transcript 2 (ILT2) and ILT4 [17]. The murine receptor paired immunoglobulin like receptor-B (PIR-B), a homology to human ILTs, can bind to HLA-G [18]. Previous findings had recognized that through binding to the PIR-B expressed on MDSCs, and HLA-G has been found with the capability to contribute the expansion and suppressive functions of MDSCs [19,20].

In addition to HLA-G exerts its regulatory functions directly by interacting with specific inhibitory receptors expressed on various immune cells, many kinds of immune cells can express HLA-G themselves which could be affected by micro environmental factors,

maturation stimuli and even by the process of trogocytosis, such as HLA-G-expressing APC, or MSC, or T or NK cells [21-24]. DC-10, a new subset of human tolerogenic DCs, is characterized by the expression of high levels of HLA-G [17]. These cells mainly act as regulatory cells, through the blocking the function of effector cells, and inducing the generation of suppressive cells.

However, whether peripheral MDSCs express HLA-G in patients infected with hepatitis B virus (HBV) remains unknown. In this study, the frequency of peripheral MDSCs (Lin1-HLA-DR-CD33+CD11b+) and HLA-G+ MDSCs subsets from HBV patients was analyzed. Our findings revealed that HLA-G+ MDSCs among peripheral blood monocytes (PBMC) were expanded in patients with chronic hepatitis B virus infection.

Materials and Methods

Study setting and participants

Consecutive blood samples were collected from 50 patients with CHB from the Taizhou Hospital of Zhejiang Province affiliated to

Wenzhou Medical College. The diagnosis was complied with the diagnostic criteria of the 2000 Xi'an Viral Hepatitis Management Scheme issued by the Chinese Society of Infectious Diseases and Parasitology, and the Chinese Society of Hepatology, of the Chinese Medical Association [25]. Briefly, a chronic hepatitis B patient is with clinical course of hepatitis B for >6 months and may have exhibited symptoms or signs of hepatitis and abnormal hepatic function on this occasion. No patients received anti-HBV agent or steroid 6 months before sampling. Subjects who infected or concurrence of HAV, HCV, HIV infections and other diseases were excluded. Samples from 27 healthy individuals without HBV infection history and with similar age and sex characteristics were included as controls. The study protocol was approved by the ethics committee of the Taizhou Hospital of Zhejiang Province, and informed consent was obtained from all of the subjects. The baseline characteristics of subjects enrolled in the study were shown in Table 1.

Variables	Controls	CHB	Correlate to parameters of CHB patients (p value)					
	n=27	n=50	MDSC	CD14 ⁺ MDSC	CD15 ⁺ MDSC	HLA-G ⁺ MDSC	HLA-G ⁺ CD14 ⁺ MDSC	HLA-G ⁺ CD15 ⁺ MDSC
Age (yrs)	45.6 ± 9.2	46.6.1 ±12.4	0.490	0.496	0.553	0.351	0.715	0.179
Sex (male/female)	16/11	38/12	0.237	0.215	0.031	0.771	0.140	0.307
HBsAg positive (%)	0	50 (100%)						
HBsAb positive (%)	0	1 (2.0%)						
HBeAg positive (%)	0	15 (30.0%)	0.072	0.534	0.150	0.808	0.643	0.244
HBeAb positive (%)	0	25 (50.0%)	0.088	0.498	0.077	0.843	0.279	0.048
HBcAb positive (%)	0	50 (100%)						
ALT (IU/L)	<40	340.5 ± 537.4	0.482	0.791	0.151	0.347	0.643	0.188
AST (IU/L)	-	170.7 ± 197.3	0.955	0.916	0.305	0.360	0.231	0.418
ALP(IU/L)	-	140.6 ± 52.4	0.609	0.380	0.091	0.027	0.952	0.438
GGT(IU/L)	-	119.0 ± 97.7	0.234	0.436	0.008	0.618	0.816	0.250
TBil (μmol/L)	-	47.1 ± 76.3	0.247	0.840	0.065	0.098	0.455	0.606
HBV DNA (log10)a	-	5.28 ± 2.04	0.833	0.371	0.063	0.665	0.295	0.032

CHB: Chronic hepatitis B patients; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; ALP: Alkaline phosphatase; GGT: Glutamyl transpeptidase; HBV: Hepatitis B virus; TBil: Total bilirubin; -: not detected.

Table 1: Baseline characteristics of the study populations.

Virological assessments

HBV serum markers were determined using commercial enzyme immunoassay kits (AXSYM System, Abbott, Wiesbaden, Germany). HBV DNA was extracted from serum samples and quantified using a commercial polymerase chain reaction (PCR) diagnostic kit with

detection limit of 100 copies/ml (Sybio, Shanghai, China). Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), γ-glutamyl transpeptidase (GGT), total bilirubin concentration levels were measured by an auto biochemical analyzer (Olympus AU 5400, Olympus Corporation, Tokyo, Japan).




Figure 1: Phenotypic analysis and frequencies of MDSCs subsets in patients with chronic HBV infection and normal controls. Flow cytometric evaluation of Lin, HLA-DR, CD33, CD11b, HLA-G, CD15, and CD14 in PBMCs. An example of representative dot plots is shown for each group. Markers for MDSCs: Lin-HLA-DR-CD33⁺CD11b⁺, gMDSCs: Lin-HLA-DR-CD33⁺CD11b⁺CD15⁺ and mMDSCs: Lin-HLA-DR-CD33⁺CD11b⁺CD14⁺. Furthermore, HLA-G expression on MDSCs, gMDSCs and mMDSCs was analyzed. Gates were set based on appropriate isotype controls. The frequency of MDSCs defined as the percentage of MDSCs among total PBMC. The frequency of gMDSCs, mMDSCs and HLA-G expressing (MDSCs, gMDSCs and mMDSCs) defined as the percentage of respective MDSC subsets among total MDSCs. The type of each MDSC subset and frequency was presented in parenthese in each plot inside.

Whole blood staining and flow cytometric analysis

The flow cytometry analysis was performed with the protocol described in a previous study [26]. Briefly, 100 μ L whole blood was taken for MDSC analysis. MDSC subsets were determined using the following antibodies: anti-lineage cocktail 1 (Lin1)-FITC, anti-HLA-DR-APC, anti-CD33-PerCP-Cy5.5, anti-CD11b-APC-Cy7, anti-CD14-PE-Cy7, anti-CD15-PE-Cy7 (BD Pharmingen, San Jose, CA), and anti-HLA-G-PE (Exbio, Modrice, Czech Republic). Six-colour flow cytometric analysis was performed on a BD Canto II flow cytometer. Analysis of the flow cytometric data was performed using the BD FACSuite software. Sample tubes were gently vortexed and incubated for 25 min at 4. After the incubation, lysis buffer (BD FACS lysing solution) was added to lyse the red blood cells and then incubated for 15 min at room temperature. The samples were washed twice with phosphate buffered saline. The pellet was resuspended in 300 μ L of flow cytometry buffer before analysis.

Statistical analysis

Statistical analysis was performed with SPSS 13.0 software (SPSS, Inc., Chicago, IL). Normality of continuous numeric data was analyzed by one-sample Kolmogorov-Smirnov test. Comparison of the percentage of MDSCs and its subsets, HLA-G+ MDSCs between

different groups was performed using the Mann-Whitney U test. The Spearman test was used to access the correlation between MDSCs subsets and clinical parameters. A two-sided p value < 0.05 was considered as statistically significant.

Results

Frequency of total and subsets of MDSCs in patients with chronic HBV infection and normal controls

Herein, both total and subsets of circulating MDSCs from patients with chronic HBV infection and normal controls were analyzed using multicolour flow cytometry. We defined the MDSCs as Lin-HLA-DR-CD33⁺CD11b⁺, gMDSCs as Lin-HLA-DR-CD33⁺CD11b⁺CD15⁺ and mMDSCs as Lin-HLA-DR-CD33⁺CD11b⁺CD14⁺. Furthermore, HLA-G expression on MDSCs, gMDSCs and mMDSCs was analyzed.

The frequency of MDSCs defined as the percentage of MDSCs among PBMC. The frequency of gMDSCs, mMDSCs and HLA-G expressing (MDSCs, gMDSCs and mMDSCs) defined as the percentage of respective MDSC subsets among MDSCs. Representative flow cytometric plots of patients with chronic HBV infection and normal controls were shown in Figure 1.

The range of the frequency of MDSCs, gMDSCs, mMDSCs was 0.02%~1.06%, 2.60%~86.4% and 7.00%~71.50% in patients with chronic HBV infection, and 0.03%~0.74%, 5.40%~36.40% and 10.50%~61.10% in normal controls, respectively. Between patients with chronic HBV infection and normal controls, no significant difference was observed for the frequency of circulating MDSCs (median: 0.30% vs. 0.29%; $p=0.884$) (Figure 2A), subsets of mMDSCs (median: 31.25% vs. 23.35%; $p=0.063$) (Figure 2B) and gMDSCs (median: 22.60% vs. 21.55%; $p=0.588$) (Figure 2C).

Frequency of HLA-G expressing on both total and subsets of MDSCs was significantly elevated in patients with chronic HBV infection

Data showed that, the range of the frequency of HLA-G expressing MDSCs, gMDSCs, mMDSCs was 0.10%~18.90%, 0.00%~7.47% and 0.00%~10.92% in patients with chronic HBV infection, and 0.00%~6.20%, 0.00%~2.22% and 0.00%~2.44% in normal controls, respectively. All of these HLA-G expressing MDSCs was significantly higher in patients with chronic HBV infection compared with normal controls, where HLA-G+ MDSCs (median: 3.30% vs. 0.50%; $p<0.001$)

(Figure 2D), HLA-G+ M-MDSCs (median: 0.99% vs. 0.00%; $p<0.001$) (Figure 2E) and HLA-G+ gMDSCs (median: 0.78% vs. 0.00%; $p<0.001$) (Figure 2F).

Correlation of MDSCs subsets to clinical parameters in patients with chronic HBV infection

We then determined whether the frequency of MDSCs subsets in patients with chronic HBV infection was associated with their clinical parameters (Table 1). Interestingly, we found that the frequency of gMDSCs was significantly higher in male patients than that in female patients (median: 23.2% vs. 15.9%; $p=0.031$) (Figure 3A), which was also positively correlated with the levels of glutamyl transpeptidase (GGT) in HBV infected patients ($r=0.372$; $p=0.008$) (Figure 3B). The frequency of HLA-G+ gMDSCs much higher in HBeAb positive than that in HBeAb negative patients (median: 1.13% vs. 0.33%; $p=0.048$) (Figure 3C) and negatively associated with the HBV DNA copies ($r=-0.310$; $p=0.032$) (Figure 3D), and the frequency of HLA-G+ MDSCs was inversely correlated with the levels of alkaline phosphatase (ALP) in HBV infected patients ($r=-0.313$; $p=0.027$) (Figure 3E).




Figure 2: Comparison of the frequency of (A) MDSCs; (B) mMDSCs; (C) gMDSCs; (D) HLA-G+ MDSCs; (E) HLA-G+ mMDSCs and (F) HLA-G+ gMDSCs between patients with chronic HBV infection and normal controls.

Discussion

MDSCs are a heterogeneous subsets of immature and progenitor myeloid cells that are characterized by their strong immunosuppressive ability, such as suppress NK and NKT cells, CD4+ and CD8+ T cells cytotoxic reactivity, modulate macrophages to an immunosuppressive M2 phenotype and induce the generation of regulatory T cells and regulatory DCs [6,27]. MDSCs have been extensively investigated and its clinical relevance was proposed in various malignancies in last two decades. However, the significance of MDSCs has been gaining its interesting in a number of viral infections [5,28].

The phenotype of murine MDSCs is CD11b+Gr1+, which according to the expression of Gr-1 recognized by antibodies to Ly6G and Ly6C, can be classified as either gMDSCs (CD11b+Ly6G+Ly6C^{low}) or mMDSCs (CD11b+Ly6G^{Chi}Ly6C^{Chi}), while cell markers for human MDSCs varies. Nevertheless, there is a growing consensus to define human MDSCs as Lin-CD11b+CD33+HLA-DR^{low/-}. Among this population, the CD14+CD15^{low/-} subsets described as the human mMDSCs and CD14⁻CD15+ subsets described as the human gMDSCs [29].




Figure 3: (A) Comparison of gMDSCs between male and female patients; (B) correlation between gMDSCs and levels of GGT; (C) comparison of HLA-G⁺ gMDSCs between the HBeAb negative and positive patients; (D) correlation between HLA-G⁺ gMDSCs and levels of HBV DNA copies and (E) between HLA-G⁺ MDSCs and levels of ALP in HBV infected patients.

HLA-G is a nonclassical HLA class I molecule which plays immune suppressive functions in various physiological and pathological situations such as fetus and transplant acceptance, immune escaping of malignant and virus-infected cells [30]. The immune tolerant properties of HLA-G acts mainly through inhibitory receptors ILT2 and ILT4. As a consequence, HLA-G could directly inhibit the functions of NK cells, CTLs, B cells, neutrophils, DCs and MDSCs [31]. HLA-G has also indirect immune-regulatory activities by inducing tolerogenic cells including HLA-G-expressing APC,

mesenchymal stem cells (MSCs), T regulatory (Treg) cells, CD4^{low} and CD8^{low} suppressor T cells, T regulatory type 1 (Tr1) cells, NK cells, and DC-10 cells [32,33]. Thus, HLA-G renders multiple effects in the suppression of immune responses.

In the context of MDSCs, interaction between HLA-G and murine cell receptor PIR-B (homology with the human ILTs) could expand the population of CD11b⁺Gr1⁺PIR-B⁺ or CD11b⁺ Ly6G⁺ MDSCs, which could decrease NK cytotoxic activity [19,20]. Moreover, in ILT-2

transgenic mice, HLA-G has been found to induce the emergence of CD11b⁺ Gr1⁺ MDSCs with an enhanced suppressive activity and directly involved in the prolongation of allogeneic skin graft survival [34].

As for HBV infection, liver-derived MDSCs could suppress the proliferation of allogeneic T cells and HBsAg-specific lymphocytes in an HBV transgenic murine model [35]. A recent finding revealed that HBsAg could promote differentiation of monocytes into M-MDSCs which could suppress HBV-specific T cell responses [36]. MDSC was also found to promote CD8⁺ T cell exhaustion by $\gamma\delta$ T cells in HBV-carrier immunocompetent mice [37]. These studies indicated that MDSCs could provide an additional means for virus to escape from host immune clearance. However, whether either peripheral MDSCs express HLA-G or its clinical relevance in patients infected with HBV remains unknown.

In contrast to previous above-mentioned studies, our data revealed that peripheral MDSCs were not significantly increased in patients with chronic HBV infection when compared to normal controls. Among total MDSCs, also no significance was observed for the mMDSC and gMDSC between the two groups. Indeed, inconsistent results for MDSCs in various virus infections were not rare among previous studies [5]. A study by Nonnenmann et al. [38] reported that peripheral MDSCs were not significantly increased in patients with chronic HCV infection, and there was no difference in MDSC based on genotype or viral load, and a similar effect was found for suppression the function of CD8⁺ T cells. In another study, mMDSCs were observed to be unrelated to HCV RNA loads, and levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT) [39].

In this study, we found HLA-G⁺ gMDSCs was negatively associated with the HBV DNA copies, and that was much higher in HBeAb positive than that in HBeAb negative patients. The data is reasonable because the viral replication suppression and viral load reduction was observed when loss of HBeAg after seroconversion by a reduced cccDNA load in the liver [40]. Also, HLA-G⁺ MDSCs was inversely correlated with the levels of ALP, gMDSCs was positively correlated with the levels of GGT in HBV infected patients. The discrepancy might be explained by the differences in viral factors among different viral isolates or virally derived factors in generation and accumulation of MDSCs over the course of infection, or even by the influence of host genetic background and/or environmental differences. In this regard, Ning et al. [39] reported that the frequency of mMDSCs in HCV infected patients had certain relevance with age, where patients older than 40 years old group had a significantly higher frequency of mMDSCs than that of age less than 40 years old group. In our study, however, we found that the frequency of gMDSCs was significantly higher in male than that in female HBV infected patients. Recently, an important study by Pallett et al. [41] revealed that, during various HBV infected disease activity, gMDSC counts changes dynamically. In that study, authors found gMDSCs were only expanded and highest during virus replication without liver damage, while the number of gMDSCs declined prior to hepatic flares. Therefore, the variation of disease activity itself could also contribute the discrepancy.

Importantly, we for the first time found that HLA-G⁺ MDSCs, and the subsets population of HLA-G⁺ mMDSC and HLA-G⁺ gMDSC were dramatically increased in patients with chronic HBV infection. The immune inhibitory roles of HLA-G-expressing cells such as APC, MSC, T cells, NK cells and DC-10 cells, have been well documented in a mount of studies [17,33]. In this scenario, LeMaout et al. [42]

addressed that HLA-G-expressing APCs could inhibit the proliferation of CD4⁺ T cells, induce CD4⁺ T cell anergy, and promote the differentiation of CD4⁺ T cells into suppressive cells. Moreover, HLA-G molecules expressing on APCs could be shed or acquired by other cells through the process of trogocytosis, might provide extra inhibitory or proapoptotic signals. Thus, HLA-G-expressing immune cells could suppress the function of effector cells directly, and/or induce the generation of suppressive cells, render multiple effects in the modulation of immune responses [31].

In summary, this work report for the first time that HLA-G⁺ MDSCs, a new population of peripheral MDSCs, were expanded in patients with chronic hepatitis B virus infection. Particularly, HLA-G⁺ gMDSC was inversely correlated to the viral DNA loads and significantly increased in HBeAb positive patients. Due to lack of functional analysis in this study, the potential immune roles of the HLA-G⁺ MDSCs population remain to be elucidated.

Limitations of the Study

In this study, potential mechanisms underlining up-regulation of HLA-G-expressing MDSCs, and biological function and clinical relevance of HLA-G-expressing MDSCs during HBV infection was not investigated.

Acknowledgments

National Natural Science Foundation of China (31370920 81372247), Science and Technology Bureau of Zhejiang Province (2016C33231, 2017C33217), and by Zhejiang Provincial program for the cultivation of high-level innovative health talents.

References

1. Liang TJ, Block TM, McMahon BJ, Ghany MG, Urban S, et al. (2015) Present and future therapies of hepatitis B: From discovery to cure. *Hepatology* 62: 1893-1908.
2. Chan SL, Wong VW, Qin S, Chan HL (2016) Infection and Cancer: The Case of Hepatitis B. *J Clin Oncol* 34: 83-90.
3. Busca A, Kumar A (2014) Innate immune responses in hepatitis B virus (HBV) infection. *Virology* 11: 22.
4. Loggi E, Gamal N, Bihl F, Bernardi M, Andreone P (2014) Adaptive response in hepatitis B virus infection. *J Viral Hepat* 21: 305-313.
5. Goh C, Narayanan S, Hahn YS (2013) Myeloid-derived suppressor cells: the dark knight or the joker in viral infections? *Immunol Rev* 255: 210-221.
6. Gantt S, Gervasi A, Jaspan H, Horton H (2014) The role of myeloid-derived suppressor cells in immune ontogeny. *Front Immunol* 5: 387.
7. Keskinov AA, Shurin MR (2015) Myeloid regulatory cells in tumor spreading and metastasis. *Immunobiology* 220: 236-242.
8. Cai W, Qin A, Guo P, Yan D, Hu F, et al. (2013) Clinical significance and functional studies of myeloid-derived suppressor cells in chronic hepatitis C patients. *J Clin Immunol* 33: 798-808.
9. Tacke RS, Lee HC, Goh C, Courtney J, Polyak SJ, et al. (2012) Myeloid suppressor cells induced by hepatitis C virus suppress T-cell responses through the production of reactive oxygen species. *Hepatology* 55: 343-353.
10. Zeng QL, Yang B, Sun HQ, Feng GH, Jin L, et al. (2014) Myeloid-derived suppressor cells are associated with viral persistence and downregulation of TCR β chain expression on CD8(+) T cells in chronic hepatitis C patients. *Mol Cells* 37: 66-73.
11. Tumino N, Turchi F, Meschi S, Lalle E, Bordoni V, et al. (2015) In HIV-positive patients, myeloid-derived suppressor cells induce T-cell anergy

- by suppressing CD3 ζ expression through ELF-1 inhibition. *AIDS* 29: 2397-2407.
12. Garg A, Spector SA (2014) HIV type 1 gp120-induced expansion of myeloid derived suppressor cells is dependent on interleukin 6 and suppresses immunity. *J Infect Dis* 209: 441-451.
 13. Jeisy-Scott V, Davis WG, Patel JR, Bowzard JB, Shieh WJ, et al. (2011) Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. *PLoS One* 6: e25242.
 14. Fortin C, Huang X, Yang Y (2012) NK cell response to vaccinia virus is regulated by myeloid-derived suppressor cells. *J Immunol* 189: 1843-1849.
 15. Zhu J, Huang X, Yang Y (2012) Myeloid-derived suppressor cells regulate natural killer cell response to adenovirus-mediated gene transfer. *J Virol* 86: 13689-13696.
 16. Rizzo R, Bortolotti D, Bolzani S, Fainardi E (2014) HLA-G Molecules in Autoimmune Diseases and Infections. *Front Immunol* 5: 592.
 17. Amodio G, Sales de Albuquerque R, Gregori S (2014) New insights into HLA-G mediated tolerance. *Tissue Antigens* 84: 255-263.
 18. Liang S, Baibakov B, Horuzsko A (2002) HLA-G inhibits the functions of murine dendritic cells via the PIR-B immune inhibitory receptor. *Eur J Immunol* 32: 2418-2426.
 19. Loumagne L, Baudhuin J, Favier B, Montespan F, Carosella ED, et al. (2014) In vivo evidence that secretion of HLA-G by immunogenic tumor cells allows their evasion from immunosurveillance. *Int J Cancer* 135: 2107-2117.
 20. Agaugué S, Carosella ED, Rouas-Freiss N (2011) Role of HLA-G in tumor escape through expansion of myeloid-derived suppressor cells and cytokinetic balance in favor of Th2 versus Th1/Th17. *Blood* 117: 7021-7031.
 21. Naji A, Durrbach A, Carosella ED, Rouas-Freiss N (2007) Soluble HLA-G and HLA-G1 expressing antigen-presenting cells inhibit T-cell alloproliferation through ILT-2/ILT-4/FasL-mediated pathways. *Hum Immunol* 68: 233-239.
 22. Najar M, Raicevic G, Fayyad-Kazan H, De Bruyn C, Bron D, et al. (2012) Immune-related antigens, surface molecules and regulatory factors in human-derived mesenchymal stromal cells: the expression and impact of inflammatory priming. *Stem Cell Rev* 8: 1188-1198.
 23. Huang YH, Zozulya AL, Weidenfeller C, Schwab N, Wiendl H (2009) T cell suppression by naturally occurring HLA-G-expressing regulatory CD4 $^{+}$ T cells is IL-10-dependent and reversible. *J Leukoc Biol* 86: 273-281.
 24. Caumartin J, Favier B, Daouya M, Guillard C, Moreau P, et al. (2007) Trogocytosis-based generation of suppressive NK cells. *EMBO J* 26: 1423-1433.
 25. Chinese Society of Infectious Diseases and Parasitology and Chinese Society of Hepatology of Chinese Medical Association (2000) National program for prevention and treatment of viral hepatitis. *Chin J Hepatol* 8: 324-329.
 26. Khaled YS, Ammori BJ, Elkord E (2014) Increased levels of granulocytic myeloid-derived suppressor cells in peripheral blood and tumour tissue of pancreatic cancer patients. *J Immunol Res* 2014: 879897.
 27. Yang WC, Ma G, Chen SH, Pan PY (2013) Polarization and reprogramming of myeloid-derived suppressor cells. *J Mol Cell Biol* 5: 207-209.
 28. Khaled YS, Ammori BJ, Elkord E (2013) Myeloid-derived suppressor cells in cancer: recent progress and prospects. *Immunol Cell Biol* 91: 493-502.
 29. Jiang J, Guo W, Liang X (2014) Phenotypes, accumulation, and functions of myeloid-derived suppressor cells and associated treatment strategies in cancer patients. *Hum Immunol* 75: 1128-1137.
 30. Carosella ED, Rouas-Freiss N, Tronik-Le Roux D, Moreau P, LeMaoult J (2015) HLA-G: An Immune Checkpoint Molecule. *Adv Immunol* 127: 33-144.
 31. Lin A, Yan WH (2015) HLA-G expression in cancers: roles in immune evasion, metastasis and target for therapy. *Mol Med*.
 32. Carosella ED, Gregori S, Rouas-Freiss N, LeMaoult J, Menier C, et al. (2011) The role of HLA-G in immunity and hematopoiesis. *Cell Mol Life Sci* 68: 353-368.
 33. Carosella ED, HoWangYin KY, Favier B, LeMaoult J (2008) HLA-G-dependent suppressor cells: Diverse by nature, function, and significance. *Hum Immunol* 69: 700-707.
 34. Zhang W, Liang S, Wu J, Horuzsko A (2008) Human inhibitory receptor immunoglobulin-like transcript 2 amplifies CD11b+Gr1 $^{+}$ myeloid-derived suppressor cells that promote long-term survival of allografts. *Transplantation* 86: 1125-1134.
 35. Chen S, Akbar SM, Abe M, Hiasa Y, Onji M (2011) Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus. *Clin Exp Immunol* 166: 134-142.
 36. Fang Z, Li J, Yu X, Zhang D, Ren G, et al. (2015) Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection. *J Immunol* 195: 4873-4883.
 37. Kong X, Sun R, Chen Y, Wei H, Tian Z (2014) $\gamma\delta$ T cells drive myeloid-derived suppressor cell-mediated CD8 $^{+}$ T cell exhaustion in hepatitis B virus-induced immunotolerance. *J Immunol* 193:1645-1653.
 38. Nonnenmann J, Stirner R, Roeder J, Jung MC, Schrödl K, et al. (2014) Lack of significant elevation of myeloid-derived suppressor cells in peripheral blood of chronically hepatitis C virus-infected individuals. *J Virol* 88: 7678-7682.
 39. Ning G, She L, Lu L, Liu Y, Zeng Y, et al. (2015) Analysis of monocytic and granulocytic myeloid-derived suppressor cells subsets in patients with hepatitis C virus infection and their clinical significance. *Biomed Res Int* 2015: 385378.
 40. Malmström S, Larsson SB, Hannoun C, Lindh M (2012) Hepatitis B viral DNA decline at loss of HBeAg is mainly explained by reduced cccDNA load--down-regulated transcription of PgrNA has limited impact. *PLoS One* 7: e36349.
 41. Pallett LJ, Gill US, Quaglia A, Sinclair LV, Jover-Cobos M, et al. (2015) Metabolic regulation of hepatitis B immunopathology by myeloid-derived suppressor cells. *Nat Med* 21: 591-600.
 42. LeMaoult J, Krawice-Radanne I, Dausset J, Carosella ED (2004) HLA-G1-expressing antigen-presenting cells induce immunosuppressive CD4 $^{+}$ T cells. *Proc Natl Acad Sci USA* 101: 7064-7069.